Literature DB >> 1980110

A monoclonal antibody directed against the human intercellular adhesion molecule (ICAM-1) modulates the release of tumor necrosis factor-alpha, interferon-gamma and interleukin 1.

D Geissler1, S Gaggl, J Möst, R Greil, M Herold, M Dietrich.   

Abstract

ICAM-1 is a cell surface glycoprotein which is one of the ligands for the leukocyte function-associated antigen (LFA-1). It is involved in leukocyte adhesion to endothelial cells as well as in immune functions requiring cell-cell contact. The quantitative expression of ICAM-1 in various cell types can be either induced or enhanced by treatment with cytokines, such as interferon-gamma (IFN-gamma), tumor necrosis factor (TNF)-alpha or interleukin 1 (IL 1), a phenomenon which results in the augmentation of binding to LFA-1-positive cells. In contrast, treatment with anti-ICAM-1 antibodies blocks this binding. A monoclonal antibody (mAb), termed 7F7, which recognizes an epitope on ICAM-1, was used to investigate the role of ICAM-1 in cytokine production by T lymphocytes and monocytes. Production of TNF-alpha. IFN-gamma and IL1 was significantly inhibited (p less than 0.01) by the incubation of mAb 7F7 with phytohemagglutinin-activated blood mononuclear cells (MNC) or isolated E rosette-positive T lymphocytes. The maximal level of inhibition was reached with 1 microgram/ml of purified antibody. A similar inhibition was obtained using saturating concentrations of 400 microliters/ml of mAb 7F7 hybridoma supernatant corresponding to an inhibitory activity of 1 microgram of purified mAb. In contrast, granulocyte/macrophage-colony-stimulating factor release showed a heterogeneous response over five experiments with an increase found in three experiments and a decrease in two experiments. Addition of increasing concentrations of supernatant or purified mAb to unstimulated MNC or T lymphocyte cultures had no effect on cytokine release. The observed inhibition of the production of TNF-alpha. IFN-gamma and IL 1 by antibody-mediated blockade of the ICAM-1 structure probably represents a negative circuit that serves to tune the activation of leukocytes and to avoid an overproduction of cytokines.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980110     DOI: 10.1002/eji.1830201210

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

Review 1.  Will complex carbohydrate ligands of vascular selectins be the next generation of non-steroidal anti-inflammatory drugs?

Authors:  J L Winkelhake
Journal:  Glycoconj J       Date:  1991-10       Impact factor: 2.916

2.  Distribution of cell adhesion molecules in skeletal muscle from patients with systemic lupus erythematosus.

Authors:  M Pallis; D K Robson; D O Haskard; R J Powell
Journal:  Ann Rheum Dis       Date:  1993-09       Impact factor: 19.103

3.  The production of chemotactic cytokines in an allogeneic response. The role of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3.

Authors:  N W Lukacs; S L Kunkel; M D Burdick; R M Strieter
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

Review 4.  Intercellular adhesion molecule-1.

Authors:  A van de Stolpe; P T van der Saag
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

5.  Role of the adhesion molecule lymphocyte function associated antigen 1 in toxic shock syndrome toxin 1-induced tumor necrosis factor alpha and interleukin-1 beta secretion by human monocytes.

Authors:  R H See; A W Chow
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

6.  Modulation of immune-associated surface markers and cytokine production by murine retinal glial cells.

Authors:  K M Drescher; J A Whittum-Hudson
Journal:  J Neuroimmunol       Date:  1996-01       Impact factor: 3.478

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.